According to Protalix BioTherapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 12.6. At the end of 2022 the company had a P/E ratio of -4.57.
Year | P/E ratio | Change |
---|---|---|
2022 | -4.57 | 241.12% |
2021 | -1.34 | -94.84% |
2020 | -25.9 | 880.23% |
2019 | -2.65 | 62.12% |
2018 | -1.63 | 61.54% |
2017 | -1.01 | -93.49% |
2016 | -15.5 | -194.32% |
2015 | 16.5 | -129.51% |
2014 | -55.8 | -57% |
2013 | -130 | -67.52% |
2012 | -399 | 142.94% |
2011 | -164 | -7.79% |
2010 | -178 | 10.37% |
2009 | -161 | 172.03% |
2008 | -59.4 | 720.49% |
2007 | -7.23 | -98.54% |
2006 | -497 | 1052.86% |
2005 | -43.1 | 1680.87% |
2004 | -2.42 | -96.97% |
2003 | -80.0 | 263.64% |
2002 | -22.0 | -4.35% |
2001 | -23.0 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Pfizer PFE | 14.9 | 18.41% | ๐บ๐ธ USA |
Neurocrine Biosciences
NBIX | 70.4 | 458.47% | ๐บ๐ธ USA |
Amicus Therapeutics
FOLD | -18.4 | -246.08% | ๐บ๐ธ USA |
Teva Pharmaceutical Industries TEVA | -7.06 | -155.99% | ๐ฎ๐ฑ Israel |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.